so I figured ahead of earnings it was time to buy some.
I see no exposure to bad loans here, they get in many cases warrants and other instruments they can cash in on in addition to interest, etc., their average loan matures in 3 years, companies (their product pipeline) looking for venture capital in health sciences and tech are only going to grow as pharma gets bigger and bigger, and they have zero exposure to anything that has pummeled others in the financial sector.
I see upside here. Am I missing something? Maybe. But I can't see it other than the fact it is not high profile.
Will be interesting to see what they report in August.
As I recall, it was not comparing HTGC to FCH and SSP, but talking about consistency of dividend payout and the percentage being high. You are, of course, spot on with regard to the comment on whether it will stop in an instant.